Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102644 | 0.89 | GPBAR1 (0.42) | GPBAR1GRM1BACE1KCNH2 | |
| SCHEMBL13005210 | 0.83 | AKT1 (0.39) | SCN10A | |
| SCHEMBL10102640 | 0.83 | HRH4 (0.41) | GPBAR1GRM1KCNH2 | |
| SCHEMBL10102661 | 0.80 | GPBAR1 (0.41) | GPBAR1GRM1BACE1KCNH2 | |
| SCHEMBL10102633 | 0.80 | RPS6KB2 (0.40) | GPBAR1SCN10A | |
| SCHEMBL3386183 | 0.80 | PIK3CG (0.40) | SCN10A | |
| SCHEMBL10102660 | 0.79 | IDO1 (0.44) | GPBAR1GRM1 | |
| SCHEMBL10102655 | 0.79 | PDE4B (0.37) | BACE1 | |
| SCHEMBL10107980 | 0.78 | SCN10A (0.35) | SCN10AKCNH2 | |
| SCHEMBL13005209 | 0.76 | SCN10A (0.34) | SCN10AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | KIF5A, KIF5C, KIF5B | GPBAR1 2259/4885GRM1 477/4885SCN10A 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.